Cargando…

Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer

Phase III studies have demonstrated the clinical benefit of adding neo-adjuvant androgen deprivation to radical radiotherapy for clinically localised prostate cancer. We have developed a nomogram to describe the probability of PSA control for patients treated in this way. Five hundred and seventeen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parker, C C, Norman, A R, Huddart, R A, Horwich, A, Dearnaley, D P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375313/ https://www.ncbi.nlm.nih.gov/pubmed/11875726 http://dx.doi.org/10.1038/sj.bjc.6600160

Ejemplares similares

Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer
por: Pechlivanis, Maree, et al.
Publicado: (2021)

Nomogram for predicting the biochemical recurrence of prostate cancer after neoadjuvant androgen deprivation therapy
por: Sun, Qi, et al.
Publicado: (2023)

Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments
por: Payne, H, et al.
Publicado: (2011)

Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?
por: Eom, Keun-Yong, et al.
Publicado: (2014)

Fertility, gonadal and sexual function in survivors of testicular cancer
por: Huddart, R A, et al.
Publicado: (2005)

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up
por: Creak, A, et al.
Publicado: (2013)

Evaluation of biochemical recurrence in patients with high-risk prostate cancer treated with radical prostatectomy and radiotherapy plus androgen deprivation therapy
por: Yamamoto, Yutaka, et al.
Publicado: (2016)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer
por: Milecki, Piotr, et al.
Publicado: (2009)

Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma
por: Horwich, A, et al.
Publicado: (2014)

Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy
por: Björeland, Ulrika, et al.
Publicado: (2021)

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer
por: Wei, Yongbao, et al.
Publicado: (2023)

The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer
por: Cook, A M, et al.
Publicado: (2000)

The modern role of androgen deprivation therapy in the management of localised and locally advanced prostate cancer
por: Gunner, Charlotte, et al.
Publicado: (2016)

Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer
por: Takakusagi, Yosuke, et al.
Publicado: (2020)

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
por: Dearnaley, D P, et al.
Publicado: (2005)

Neoadjuvant Androgen Deprivation Therapy Effects on Perioperative Outcomes Prior to Radical Prostatectomy: Eleven Years of Experiences at Ramathibodi Hospital
por: Sangkum, Premsant, et al.
Publicado: (2021)

Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer
por: White, I D, et al.
Publicado: (2015)

Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer
por: Ferreira, M.R., et al.
Publicado: (2019)

Neoadjuvant versus Concurrent Androgen Deprivation Therapy in Localized Prostate Cancer Treated with Radiotherapy: A Systematic Review of the Literature
por: Cartes, Rodrigo, et al.
Publicado: (2023)

A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer
por: Portner, R., et al.
Publicado: (2021)

Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
por: Amit, Uri, et al.
Publicado: (2019)

Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
por: Lu, Yu-Cheng, et al.
Publicado: (2022)

Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: When to perform radical prostatectomy?
por: Xu, Ziyang, et al.
Publicado: (2022)

Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
por: Røe, Kathrine, et al.
Publicado: (2012)

Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study
por: Haque, Reina, et al.
Publicado: (2017)

Adding radiotherapy to androgen deprivation therapy in men with node-positive prostate cancer after radical prostatectomy: A meta-analysis
por: Guo, Lijuan, et al.
Publicado: (2020)

Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
por: Heesterman, Berdine L., et al.
Publicado: (2023)

Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer
por: Wilkins, Anna, et al.
Publicado: (2015)

Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer
por: Mason, Malcolm D., et al.
Publicado: (2015)

Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy
por: Blute, Michael L., et al.
Publicado: (2017)

Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer
por: Salji, M, et al.
Publicado: (2014)

Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy
por: Utsumi, Takanobu, et al.
Publicado: (2023)

Microsatellite instability in human testicular germ cell tumours.
por: Huddart, R. A., et al.
Publicado: (1995)

Infiltrating immune cells in prostate cancer tissue after androgen deprivation and radiotherapy
por: Erlandsson, Ann, et al.
Publicado: (2023)

Evaluation of nurse-led follow up for patients undergoing pelvic radiotherapy
por: Faithfull, S, et al.
Publicado: (2001)

Combining androgen deprivation and radiation therapy in the treatment of localised prostate cancer: Summary of level 1 evidence and current gaps in knowledge
por: Baude, Jérémy, et al.
Publicado: (2022)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer
por: Aggarwal, Rahul, et al.
Publicado: (2022)

Nomogram for Predicting Survival in Advanced Gastric Cancer after Neoadjuvant Chemotherapy and Radical Surgery
por: Chen, Yonghe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dgaooiihua0p4vv5e5h9di71l5